 |
|
|
| |
Good practice hepatitis C screening and linkage to care
initiatives at the SLTC Summit 2020: three out of four
diagnosed patients were able to start direct-acting antiviral treatment
|
| |
| |
EASL International Liver Congress, June 23-26, 2021
J CABEZAS,1,2 D COHEN,3 C FRASER,4 A GIORGINI,5 D LARREY,6 A MAIERON,7 A MARTINEZ,8 C HERNANDEZ,9 M O'SULLIVAN,10 A J REMY,11
J ROSENAU,12 P RYAN,13 A USTIANOWSKI,14 T WINDELINCKX,15 M-L YU16
1. Marqués de Valdecilla University Hospital, Santander, Spain; 2. Valdecilla Research Institute, Santander, Spain; 3. Maccabi Healthcare Services, Tel Aviv, Israel; 4. Cool Aid Community Health Centre, Victoria, Canada; 5. ASST Santi Paolo e Carlo, Milan, Italy; 6. University Hospital of Montpellier, Montpellier, France; 7. University Hospital St. Pölten, St. Pölten, Austria; 8. Erie County Medical Center, Buffalo, USA;
9. Gilead Sciences, Stockley Park, UK; 10. Brighton and Sussex University Hospital, Brighton, UK; 11. Hospital Centre of Perpignan, Perpignan, France; 12. University of Kentucky Medical Center, Lexington, USA; 13. Infanta Leonor Teaching Hospital, Madrid, Spain; 14. North Manchester General Hospital, Manchester, UK; 15. Free-Clinic, Antwerp, Belgium; 16. Kaohsiung Medical University, Kaohsiung, Taiwan.
REFERENCES: 1. World Health Organization Hepatitis C Factsheet. 27 July 2020. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed 15 April 2021); 2. World Health Organization Advocacy Brief: Combating Hepatitis B and C to Reach Elimination by 2030. May 2016. Available at: https://www.who.int/hepatitis/
publications/hep-elimination-by-2030-brief/en/ (accessed 15 April 2021); 3. European Association for the Study of the Liver. J Hepatol 2020;73:1170-218; 4. AASLD/EASL/APASL/ALEH. Call to Action for Liver Associations to Advance Progress Towards Viral Hepatitis Elimination: A Focus on Simplified Approaches to HCV Testing and Cure. 2019.
https://www.aasld.org/sites/default/files/2019-11/2019-HCVElimination-CallToAction-v2.pdf (accessed 19 April 2021); 5. Noska AJ, et al. Public Health Rep 2017;132:136-9; 6. Nyamathi A, et al. J Forensic Nurs 2013;9:161-70.
ABBREVIATIONS: Ab, antibody; DAA, direct-acting antiviral; HCV, hepatitis C virus; PWID, people who inject drugs; Rx, treatment; SLTC, screening and linkage to care; SVR, sustained virological response.
ACKNOWLEDGMENTS: This study was funded by Gilead Sciences. The authors thank Karen Beckett PhD from Elements Communications for providing medical writing support. This service was funded by Gilead Sciences, in accordance with Good Publication Practice (GPP3) guidelines.
DISCLOSURES: Speaking/consulting/research: J Cabezas (Abbvie, Gilead Sciences, Merck Sharp & Dohme), C Fraser (Abbvie, Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare), A Giorgini (Abbvie), D Larrey (Abbvie, Gilead Sciences), A Maieron (Abbvie, Gilead Sciences), A Martinez (Abbvie, Bayer, Gilead Sciences, Intercept, Merck Sharp & Dohme, Salix, Tobira), M O'Sullivan (Gilead Sciences), A J Remy (Abbvie, Gilead Sciences, Merck Sharp & Dohme), J Rosenau (Abbvie, Gilead Sciences), P Ryan (Abbvie, Gilead Sciences, Janssen, Merck Sharp & Dohme, ViiV Healthcare), A Ustianowski (Abbvie, Gilead Sciences, Janssen, Merck Sharp & Dohme, UCB, ViiV Healthcare), T Windelinckx (Abbvie, Gilead Sciences, MSD), M-L Yu (Abbott, Abbvie, Ascletis, BMS, Gilead Sciences, IPSEN, Merck Sharp & Dohme, Roche). Gilead employee: C Hernandez. Nothing to declare: D Cohen.
|
| |
|
|
|
|
|
